Total Clarity Wealth Management’s MaxCyte MXCT Stock Holding History

Total Clarity Wealth Management’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,518	Closed	-$7K	–	704
2022 Q2	$7K	Buy	+1,518	New	+$7.48K	﹤0.01%	754
2022 Q1	–	Sell	-579	Closed	-$6K	–	648
2021 Q4	$6K	Buy	+579	New	+$6.22K	﹤0.01%	787

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

Total Clarity Wealth Management's MXCT Position: Q3 2022 in Review

Total Clarity Wealth Management sold out of MaxCyte (MXCT) in Q3 2022, closing a stake of 1,518 shares — an estimated $7K sold.

Total Clarity Wealth Management first reported a position in MXCT in Q4 2021 and held it in 2 quarters. The position peaked at $7K in Q2 2022. 108 funds tracked by Wall St. Rank hold MXCT as of Q3 2022.

Total Clarity Wealth Management reported no remaining MaxCyte position as of Q3 2022 after selling out during the quarter.
Total Clarity Wealth Management sold 1,518 MaxCyte shares in Q3 2022, an estimated $7K.
Total Clarity Wealth Management first reported a position in MaxCyte in Q4 2021 and held it in 2 quarters.
Total Clarity Wealth Management's MaxCyte position peaked at $7K in Q2 2022.
108 funds tracked by Wall St. Rank held MaxCyte as of Q3 2022.

Based on Total Clarity Wealth Management's 13F filing for Q3 2022, filed 4 Nov 2022.